Product Description
Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough
Mechanisms of Action: P2X3 Antagonist
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Evotec
Company Location: HAMBURG 2M 22525
Company CEO:
Additional Commercial Interests: Bayer
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Overactive Bladder|Unexplained Chronic Cough|Refractory Chronic Cough|Endometriosis|Peripheral Nervous System Diseases|Neuropathic Pain|Neuralgia
Phase 1: Refractory Chronic Cough|Overactive Bladder|Neuropathic Pain|Chronic Pain|Neuralgia|Endometriosis|Unexplained Chronic Cough|Chronic Cough|Healthy Volunteers|Male Breast Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| jRCT2031210001 | P2 |
Completed |
Endometriosis |
2022-05-03 |
|||
| SCHUMANN | P2 |
Completed |
Endometriosis |
2022-05-03 |
50% |
2022-03-13 |
Treatments |
| Ovader | P2 |
Completed |
Overactive Bladder |
2022-01-21 |
50% |
2022-03-13 |
Treatments |
| SCHUMANN | P2 |
Terminated |
Endometriosis |
2022-01-17 |
50% |
2023-06-02 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Treatments|Trial Status |
| OVADER | P2 |
Completed |
Overactive Bladder |
2021-12-22 |
50% |
2022-02-12 |
Primary Completion Date|Primary Endpoints|Study Completion Date |
| 2020-002066-14 | P2 |
Terminated |
Neuropathic Pain |
2021-12-17 |
48% |
2025-07-09 |
Treatments |
| CTR20210308 | P1 |
Completed |
Chronic Cough |
2021-10-29 |
2025-04-29 |
Patient Enrollment|Treatments |
|
| NCT04641273 | P2 |
Terminated |
Neuralgia|Peripheral Nervous System Diseases|Neuropathic Pain |
2021-09-23 |
48% |
2022-03-04 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date |
| jRCT2031200185 | P2 |
Completed |
Unexplained Chronic Cough|Refractory Chronic Cough |
2021-07-23 |
|||
| PAGANINI | P2 |
Completed |
Unexplained Chronic Cough|Refractory Chronic Cough |
2021-07-23 |
47% |
2022-03-13 |
Treatments |
| NCT04802343 | P1 |
Completed |
Chronic Cough |
2021-07-19 |
50% |
2021-11-25 |
Primary Endpoints|Treatments|Trial Status |
| NCT04454424 | P1 |
Completed |
Overactive Bladder|Refractory Chronic Cough|Unexplained Chronic Cough|Neuralgia|Endometriosis|Chronic Pain|Neuropathic Pain |
2021-06-24 |
12% |
2022-01-07 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| PAGANINI | P2 |
Completed |
Unexplained Chronic Cough|Refractory Chronic Cough |
2021-06-22 |
47% |
2021-09-24 |
Primary Endpoints|Study Completion Date|Treatments |
| NCT04471337 | P1 |
Completed |
Chronic Pain|Unexplained Chronic Cough|Neuralgia|Neuropathic Pain|Endometriosis|Refractory Chronic Cough|Overactive Bladder |
2021-02-15 |
12% |
2021-06-08 |
Primary Endpoints |
| TQT Study | P1 |
Completed |
Endometriosis|Overactive Bladder |
2020-11-09 |
12% |
2024-11-27 |
Primary Endpoints|Treatments |
| NCT04487431 | P1 |
Completed |
Neuropathic Pain|Unexplained Chronic Cough|Overactive Bladder|Chronic Pain|Neuralgia|Refractory Chronic Cough|Endometriosis |
2020-09-30 |
50% |
2022-05-27 |
Primary Endpoints|Treatments |
| NCT04265781 | P1 |
Completed |
Neuropathic Pain|Chronic Pain|Overactive Bladder|Unexplained Chronic Cough|Neuralgia|Refractory Chronic Cough|Endometriosis |
2020-09-20 |
88% |
2021-05-12 |
Primary Endpoints|Treatments |
| NCT04252300 | P1 |
Completed |
Chronic Cough|Male Breast Cancer|Chronic Pain |
2020-08-29 |
50% |
2020-12-24 |
|
| NCT03773068 | P1 |
Completed |
Unexplained Chronic Cough|Refractory Chronic Cough|Endometriosis |
2019-06-21 |
50% |
2019-08-21 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
| NCT03310645 | P2 |
Completed |
Refractory Chronic Cough|Unexplained Chronic Cough |
2019-05-28 |
13% |
2023-01-27 |
Primary Endpoints |
| NCT02817100 | P1 |
Completed |
Healthy Volunteers |
2017-05-11 |
2019-03-20 |
Treatments |
|
| CTR20210645 | P2 |
Unknown |
Endometriosis |
None |
2025-04-29 |
Patient Enrollment|Start Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
02/04/2022 |
News Article |
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets |
|
07/19/2021 |
News Article |
Chronic Refractory Cough Market Size To Experience Subsequent Growth at a CAGR of 6.57% During the Study Period 2018-2030 |
|
03/11/2021 |
News Article |
Chronic Refractory Cough Market - Market Insight, Epidemiology and Market Forecast - 2030 - ResearchAndMarkets.com |
|
07/23/2020 |
News Article |
Insights on the H1 2020 Pipeline Review for P2X Purinoceptor 3 - ResearchAndMarkets.com |